This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ChromaDex® Announces First Patent Issued For Pterostilbene, The Novel Ingredient In Its BluScience™ Line Of Dietary Products

IRVINE, Calif., April 5, 2012 /PRNewswire/ -- The U.S. Patent and Trademark Office has granted patent #8,133,917 pertaining to the ingredient pterostilbene, which is licensed exclusively to ChromaDex Corp. (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of BluScience (, its new line of dietary supplements.


This is the first ChromaDex-licensed patent issued for pterostilbene, while several more patents are pending.

The three key claims of the pterostilbene patent, which encompass both the nutraceutical market and the pharmaceuticals market, relate to:
  1. A method of lowering lipid levels and to treat or reduce the risk of dyslipidemias in an individual through an effective amount of edible nutraceutical composition consisting of isolated or chemically-synthesized pterostilbene and a nutraceutically acceptable carrier;
  2. A method of lowering lipid levels in an individual through an effective amount of edible pharmaceutical composition consisting of isolated or chemically-synthesized pterostilbene and a pharmaceutically acceptable carrier; and 
  3. A method to treat or reduce the risk of dyslipidemias in an individual at risk of cardiovascular disease through an effective amount of edible pharmaceutical composition consisting of isolated or chemically-synthesized pterostilbene and a pharmaceutically acceptable carrier.

The patent application was initially filed in August 2004 by the U.S. Department of Agriculture. Subsequently, ChromaDex was granted an exclusive worldwide license to all rights in this patent of pterostilbene from the University of Mississippi and the Agricultural Research Service, which is the principal intramural scientific agency of the U.S. Department of Agriculture. The term of the license is up to and including the expiration of various pterostilbene patents and patents pending held by the licensors.

ChromaDex's proprietary pterostilbene, branded as pTeroPure®, was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan and is the key novel ingredient in BluScience, ChromaDex's new line of dietary supplements. 

Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other antioxidant polyphenols (phytochemicals that tend to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs